"All we are saying, Mr. Jrgensen, is treat the American people the same way that you treat people all over the world. Stop ripping us off," Senators urged, highlighting the inconsistent pricing for Ozempic and Wegovy.
"Bottom line is, you are charging the American people substantially more for the same exact drug than you are charging people in other countries. And my question is, why?" Sanders interrogated the rationale behind the higher U.S. prices.
Jrgensen responded that Novo Nordisk is investing $30 billion to increase production and access to the drugs but pointed to the complexities of the U.S. healthcare system as a significant factor in pricing.
"We are very committed to make sure that Americans have access at an affordable price," Jrgensen insisted, while acknowledging the ongoing challenges with affordability and access.
Collection
[
|
...
]